Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QDYQ | ISIN: CA00489Y7090 | Ticker-Symbol: 0VZ2
Frankfurt
12.11.24
08:11 Uhr
0,099 Euro
+0,001
+0,51 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACREAGE HOLDINGS INC CL D Chart 1 Jahr
5-Tage-Chart
ACREAGE HOLDINGS INC CL D 5-Tage-Chart
RealtimeGeldBriefZeit
0,1110,27007:26
GlobeNewswire (Europe)
420 Leser
Artikel bewerten:
(2)

Acreage Holdings, Inc.: Acreage Announces Executive Leadership Transition

Finanznachrichten News

NEW YORK, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Acreage Holdings, Inc. ("Acreage" or the "Company") (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the U.S., announced that Philip Himmelstein, Vice President of Financial Planning & Analysis at Acreage, will be assuming the role of Interim Chief Financial Officer, effective December 31, 2023. Carl Nesbitt has elected to step down from his role as Chief Financial Officer to pursue new opportunities, effective December 31, 2023. Mr. Nesbitt has also resigned from the Board of Directors of the Company, effective immediately.

"Philip has been an integral member of Acreage for a number of years, and we are very pleased to welcome him to the executive team," said Dennis Curran, Chief Executive Officer and Chairman of Acreage. "Philip has demonstrated outstanding leadership and played a crucial role in several Company milestones, including the streamlining of our operations and recent enterprise resource planning rollout. We are confident that he brings the required strategic oversight and financial acumen to guide us as we work towards the completion of our transaction with Canopy Growth Corporation."

Philip Himmelstein joined Acreage in September 2020, with 17 years of experience in health care and financial services before joining the cannabis industry. Philip has held leadership roles in financial planning & analysis at Blackrock and operational finance and controllership roles at NYU Langone Medical Center. At Acreage, he has led the FP&A team and has contributed to various corporate development and strategic planning initiatives.

Curran continued, "Carl has been a valued member of the Acreage team, and on behalf of the Company and the Board, I'd like to thank him for his contributions. We wish him all the best as he pursues new opportunities."

About Acreage Holdings, Inc.

Acreage is a multi-state operator of cannabis ?cultivation and retailing facilities in the U.S., including the Company's national retail store ?brand, The Botanist. With its principal address in New York City, Acreage's wide range of national and regionally available cannabis products include the award-winning brands The Botanist and Superflux, the Prime medical brand in Pennsylvania, and others. Since its founding in 2011, Acreage has focused on building and scaling operations to create a seamless, consumer-focused, branded experience. Learn more at www.acreageholdings.com and follow us on Twitter, LinkedIn, Instagram, and Facebook.

Forward Looking Statements

This news release and each of the documents referred to herein contains "forward-looking information" and ??"forward-looking statements" within the meaning of applicable Canadian and United States securities legislation, ?respectively. All statements, other than statements of historical fact, included herein are forward-looking ?information. ?Often, but not always, forward-looking statements and information can be identified by the use of words such as ??"plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", ?or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", ???"would", "might" or "will" be taken, occur or be achieved. ?

Forward-looking statements or information involve known and unknown risks, uncertainties, and other ?factors which may cause the actual results, performance or achievements of Acreage or its ?subsidiaries to be materially different from any future results, performance or achievements expressed or ?implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including, but not limited to: the occurrence of changes in U.S. federal Laws regarding the cultivation, distribution or possession of marijuana; ?the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court ?and Floating Shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Floating Share ?Arrangement Agreement; the ability of Canopy Growth Corporation ("Canopy"), Canopy USA, LLC ("Canopy USA") and Acreage to satisfy, in a timely manner, the closing conditions to the floating share arrangement among Canopy, Canopy USA and Acreage (the "Floating Share Arrangement"); risks relating to the value and liquidity of the Floating Shares and the common shares of Canopy; Canopy maintaining compliance with the Nasdaq Global Stock Market (the "Nasdaq") and Toronto Stock Exchange listing requirements; the rights of the Floating ?Shareholders may differ materially from those of shareholders in Canopy; expectations regarding future investment, growth and ?expansion of Acreage's operations; the possibility of adverse U.S. or Canadian tax consequences upon completion of the Floating Share Arrangement; if Canopy USA acquires the Fixed Shares pursuant to the Existing Arrangement Agreement without structural amendments to Canopy's interest in Canopy ?USA, the listing of the Canopy Shares on the Nasdaq may be jeopardized; the risk of a change of ?control of either Canopy or Canopy USA; restrictions on Acreage's ability to pursue certain business ?opportunities and other restrictions on Acreage's business; the impact of material non-recurring expenses in ?connection with the Floating Share Arrangement on Acreage's future results of operations, cash flows and ?financial condition; the possibility of securities class action or derivatives lawsuits; in the event that the Floating ?Share Arrangement is not completed, but the acquisition by Canopy of the Fixed Shares (the "Acquisition") is completed pursuant to Existing Arrangement Agreement and Canopy becomes the majority ?shareholder in Acreage, the likelihood that the Floating Shareholders will have little or no influence on the conduct ?of Acreage's business and affairs; risk of situations in which the interests of Canopy USA and the interests of ?Acreage or shareholders of Canopy may differ;? Acreage's compliance with Acreage's business plan for the fiscal years ending December 31, 2020 through December 31, 2029 pursuant to the Existing Arrangement Agreement; in the event that the Floating Share Arrangement is ?completed, the likelihood of Canopy completing the Acquisition in accordance with the Existing Arrangement Agreement; ?risks relating to certain directors and executive officers of Acreage having interests in the transactions ?contemplated by the Floating Share Arrangement Agreement and the connected transactions that are different ?from those of the Floating Shareholders; risks relating to the possibility that holders of more than 5% of the ?Floating Shares may exercise dissent rights; other expectations and assumptions concerning the transactions ?contemplated between Canopy, Canopy USA and Acreage; the available funds of Acreage and the anticipated ?use of such funds; the availability of financing opportunities for Acreage and Canopy USA and the risks ?associated with the completion thereof; regulatory and licensing risks; the ability of Canopy, Canopy USA and ?Acreage to leverage each other's respective capabilities and resources; changes in general economic, business ?and political conditions, including changes in the financial and stock markets; risks relating to infectious diseases, ?including the impacts of the COVID-19; legal and regulatory risks inherent in the cannabis industry, including the ?global regulatory landscape and enforcement related to cannabis, political risks and risks relating to regulatory ?change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the ?interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry?; and such other risks disclosed in the Circular, the Company's Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023 and the Company's other public filings, in each case filed with the SEC on the EDGAR website at www.sec.gov and with Canadian securities regulators and available under Acreage's profile on SEDAR at www.sedar.com. Although Acreage has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Although Acreage believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and Acreage does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Service Provider, nor any securities regulatory authority in Canada, the United States or any other jurisdiction, has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.?

For more information, contact:

Philip Himmelstein
investors@acreageholdings.com
646 600 9181

Courtney Van Alstyne
MATTIO Communications
acreage@mattio.com


© 2023 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.